Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
27.00    0.75 (2.86%)
Bid:
26.30
Ask:
27.00
Spread: 0.70 (2.662%)
Market Cap: £116.17m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Appointment of CEO

25 Mar 2025 07:00

RNS Number : 9656B
EKF Diagnostics Holdings PLC
25 March 2025
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Appointment of CEO

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces the appointment of Gavin Jones as Chief Executive Officer and to the EKF Board, with immediate effect. Gavin previously served as Chief Product Officer at EKF and has extensive industry experience in Analytical Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for the foreseeable future.

 

In his role as Chief Product Officer, Gavin led the Product Management, R&D, Marketing and Regulatory departments, bringing new and updated products to market, delivering on enhanced connectivity solutions and user-friendly design to meet evolving customer needs. Before joining EKF in 2013, Gavin held a Product Management role at Biotage AB and analyst positions at PCI (then trading as Penn Pharma) and the Forensic Science Service, initially starting out in the laboratory but quickly transitioning to product strategy and innovation. His expertise spans commercial strategy, business development, and product lifecycle management, contributing to significant growth in global healthcare markets.

 

Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from Liverpool John Moores University and has a track record of driving product innovation and operational excellence. Gavin is committed to expanding EKF's point-of-care solutions and strengthening its market presence in Life Sciences. 

 

Julian Baines, Executive Chair of EKF, commented: "I'm delighted that Gavin Jones is taking on the role as Chief Executive Officer and joining the Board. Gavin has over twenty years of experience in Point-of-Care and Life Sciences and has been instrumental in driving the commercial success of many of our products. Many shareholders have met Gavin over the last year or so as he's become more and more involved in the senior leadership team. Gavin has ambitious plans for delivering sustainable growth and unlocking the unrealised potential that our core products and service hold. We have an exciting opportunity to increase our commercial investment to drive organic growth and I'm delighted that Gavin will lead that process."

 

Additional Disclosures Required under the AIM Rules for Companies

Gavin Joseph Jones (aged 44) holds no shares in the Company and has held no directorship or partnerships in the past five years.

 

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Oliver Platts

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUQGWUPAPPC
Date   Source Headline
15th Jun 202612:36 pmRNSShare Buyback
12th Jun 20267:00 amRNSShare Buyback
11th Jun 20267:00 amRNSShare Buyback
20th May 20265:41 pmRNSLong Term Incentive Plan Award
19th May 202612:24 pmRNSResult of AGM
19th May 20267:00 amRNSAGM statement & positive Q1 trading update
27th Apr 20267:00 amRNSBoard Changes
24th Apr 20264:43 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSAcquisition of assets from Beep Insights
10th Apr 20269:12 amRNSShare Buyback
8th Apr 20262:33 pmRNSShare Buyback
7th Apr 20261:09 pmRNSShare Buyback
2nd Apr 20267:00 amRNSShare Buyback
31st Mar 20265:59 pmRNSShare Buyback
24th Mar 20267:00 amRNSFull year results
20th Mar 202611:25 amRNSShare Buyback
19th Mar 202611:20 amRNSShare Buyback
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20269:58 amRNSShare Buyback
6th Mar 20267:00 amRNSShare Buyback
5th Mar 20267:00 amRNSNotice of Results
3rd Mar 20267:00 amRNSThree-year Hematology purchasing agreement
2nd Mar 20263:30 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSShare Buyback
19th Feb 20267:00 amRNSShare Buyback Programme
2nd Feb 20267:00 amRNSShare Buyback & Completion of Buyback Programme
30th Jan 20267:00 amRNSShare Buyback
29th Jan 20267:00 amRNSShare Buyback
28th Jan 202611:41 amRNSShare Buyback
27th Jan 20267:00 amRNSFY 2025 Trading Update
15th Jan 20267:00 amRNSShare Buyback
14th Jan 202611:43 amRNSShare Buyback
14th Jan 20269:37 amRNSShare Buyback
12th Jan 20269:45 amRNSShare Buyback
9th Jan 20265:00 pmRNSShare Buyback
8th Jan 20269:40 amRNSShare Buyback
6th Jan 20266:03 pmRNSShare Buyback
2nd Jan 202610:23 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.